Investors are overlooking Jiangsu Gdk Biological Technology's recent poor growth, hoping for a business turnaround. However, unless conditions improve significantly, the share price may be hard to accept as fair value.

Jiangsu Gdk Biological Technology's high P/S ratio contrasts its declining revenue. Future disappointments for investors may follow if these align with the company's negative growth rates.